

## Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

### Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
F	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: April 15<sup>th</sup> 2017

State Party to the Convention: Japan

Date of ratification/accession to the Convention: 8 June 1982

National point of contact: Eva NAKAMURA, Ministry of Foreign Affairs of Japan

## Confidence-Building Measure "A"

### Part 1 Exchange of data on research centres and laboratories

#### Form A, part 1 (i)

*Exchange of data on research centres and laboratories<sup>1</sup>*

(1)

1. Name(s) of facility **RIKEN Tsukuba Campus**
2. Responsible public or private organization or company **The Institute of Physical and Chemical Research (RIKEN)**
3. Location and postal address **3-1-1, Koyadai, Tsukuba-shi, Ibaraki, 305-0074, JAPAN**
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence  
**Ministry of Education, Culture, Sports, Science and Technology**
5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m<sup>2</sup>)  
**2 units, 82 m<sup>2</sup> × 2**
6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate  
**Risk assessment of recombinant DNA materials using Retrovirus**

---

<sup>1</sup> The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

(2)

1. Name(s) of facility **Murayama Annex of National Institute of Infectious Diseases (former National Institute of Health)**
2. Responsible public or private organization or company **Ministry of Health, Labour and Welfare**
3. Location and postal address **Gakuen4-7-1, Musashimurayama, Tokyo, 208-0011, Japan**
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence  
**Ministry of Health, Labour and Welfare**
5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m<sup>2</sup>)  
**Three P4 Laboratories, Seventeen P3 Laboratories and their supporting Laboratories (2,270.36 m<sup>2</sup> in totals)**
6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate  
**Laboratory diagnosis of viral haemorrhagic fever such as Lassa, Marburg and Ebola diseases (However, such diagnosis has never been performed in these laboratories so far).**

**Part 2 Exchange of information on national biological defence research and development programmes**

**Form A, part 2 (i)**

**National biological defence research and development programmes  
Declaration**

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes  No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

**Form A, part 2 (ii)**

**National biological defence research and development programmes**

**Description**

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

**The Japan Ground Self-Defense Force's biological defense research and development programmes for FY2016 includes; Research of molecular biological diagnosis for biological agent casualties**

2. State the total funding for each programme and its source.

**Approximately 1,504,000 Japanese yen, funded by the Ministry of Defense**

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes  No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).
7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

**Form A, part 2 (iii)**

**National biological defence research and development programmes**

**Facilities**

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

**Military Medicine Research Unit, Test & Evaluation Command, Japan Ground Self-Defense Force**

2. Where is it located (include both address and geographical location)?

**1-2-24, Ikejiri Setagaya-ku, Tokyo 154-0001, Japan**

3. Floor area of laboratory areas by containment level:

BL2 Approximately 42 (sqM)

BL3 0 (sqM)

BL4 0 (sqM)

Total laboratory floor area 104 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel \_\_\_\_\_

(ii) Division of personnel:

Military \_\_\_\_\_

Civilian \_\_\_\_\_

(iii) Division of personnel by category:

Scientists \_\_\_\_\_

Engineers \_\_\_\_\_

Technicians \_\_\_\_\_

Administrative and support staff \_\_\_\_\_

(iv) List the scientific disciplines represented in the scientific/engineering staff.

**Ph.D.in Medicine**

(v) Are contractor staff working in the facility? If so, provide an approximate number.

**No**

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

**The Ministry of Defense (wholly)**

(vii) What are the funding levels for the following programme areas:

Research **cannot be divided into each area**

Development **cannot be divided into each area**

Test and evaluation **cannot be divided into each area**

(viii) Briefly describe the publication policy of the facility:

**Authorization by the MOD.**

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

**None**

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms<sup>2</sup> and/or toxins studied, as well as outdoor studies of biological aerosols.

**Research and Development of medical diagnosis/treatment and prevent medicine for casualties in action.**

---

<sup>2</sup> Including viruses and prions.

## Confidence-Building Measure "C"

### Encouragement of publication of results and promotion of use of knowledge

The Government of Japan maintains an open policy on the exchange of information on biological research, the results of such research being made freely available in all cases where the release is not prejudicial to vital national or commercial interests. This policy would apply to any research subject to the reporting in Forms A and B.

(1) Relevant information is available at the following site.

1) Lists of scientific papers in English and Japanese, which are published by the staffs of National Institute of Infectious Disease (NIID), can be seen in the web site of NIID.

<http://www.nih.go.jp/niid/en/>

2) NIID publishes bimonthly Japanese Journal of Infectious Diseases (JJID), the leading infectious disease journal in Japan. JJID receives more than 250 manuscripts per year from authors around the world. It has been donated to more than 75 countries. JJID is available at the journal site.

<http://www.nih.go.jp/niid/en/>

3) Information relevant to cDNA is available at the journal site.

<http://www.sciencedirect.com/science/article/pii/S0034528816300637>

(2) Selected articles published in the journal :

**Iizuka I, Ami Y, Suzaki Y, Nagata N, Fukushi S, Ogata M, Morikawa S, Hasegawa H, Mizuguchi M, Kurane I, Saijo M. A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox. Jpn J Infect Dis. 2016 Dec22; in press.**

**Kaneyuki S, Yoshikawa T, Tani H, Fukushi S, Taniguchi S, Fukuma A, Shimojima M, Kurosu T, Morikawa S, Saijo M. Ulcerative lesions with hemorrhage in a patient with severe fever with thrombocytopenia syndrome observed via upper gastrointestinal endoscopy. Jpn J Infect Dis. 2016, 69(6): 525-527.**

**Hotta A, Tanabayashi K, Fujita O, Shindo J, Park CH, Kudo N, Hatai H, Oyamada T, Yamamoto Y, Takano A, Kawabata H, Sharma N, Uda A, Yamada A, Morikawa S. Survey of Francisella tularensis in Wild Animals in the Endemic Areas in Japan. Jpn J Infect Dis. 2016, 69(5):431-4.**

3) Publications in other journals

**Kimura M, Une Y, Suzuki M, Park E-S, Imaoka K and Morikawa S. Isolation of *Brucella inopinata*-like bacteria from White's and Denny's tree frogs. *Vector Borne Zoonotic Dis.* in press.**

**Arai S, Taniguchi S, Aoki K, Yoshikawa Y, Kyuwa S, Tanaka-Taya K, Masangkay JS, Omatsu T, Puentespina R Jr, Watanabe S, Alviola P, Alvarez J, Eres E, Cosico E, Quibod MN, Morikawa S, Yanagihara R, Oishi K. Molecular phylogeny of a genetically divergent hantavirus harbored by the Geoffroy's rousette (*Rousettus amplexicaudatus*), a frugivorous bat species in the Philippines. *Infect Genet Evol.* 2016; 45:26-32.**

**Uda A, Sharma N, Takimoto K, Deyu T, Koyama Y, Park ES, Fujita O, Hotta A, Morikawa S. Pullulanase Is Necessary for the Efficient Intracellular Growth of *Francisella tularensis*. *PLoS One.* 2016;11(7):e0159740.**

**Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, Sato Y, Suzuki T, Nagata N, Hasegawa H, Kawai Y, Uda A, Morikawa S, Shimojima M, Watanabe H, Saijo M. Efficacy of T-705 (Favipiravir) in the treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus. *mSphere.* 2016;1(1).**

**Arai S, Kang HJ, Gu SH, Ohdachi SD, Cook JA, Yashina LN, Tanaka-Taya K, Abramov SA, Morikawa S, Okabe N, Oishi K, Yanagihara R. Genetic Diversity of Artybash Virus in the Laxmann's Shrew (*Sorex caecutiens*). *Vector Borne Zoonotic Dis.* 2016;16(7):468-75.**

**Fukuma A, Fukushi S, Yoshikawa T, Tani H, Taniguchi S, Kurosu T, Egawa K, Suda Y, Singh H, Nomachi T, Gokuden M, Ando K, Kida K, Kan M, Kato N, Yoshikawa A, Kitamoto H, Sato Y, Suzuki T, Hasegawa H, Morikawa S, Shimojima M, Saijo M. Severe Fever with Thrombocytopenia Syndrome Virus Antigen Detection Using Monoclonal Antibodies to the Nucleocapsid Protein. *PLoS Negl Trop Dis.* 2016;10(4):e0004595.**

**Tani H, Shimojima M, Fukushi S, Yoshikawa T, Fukuma A, Taniguchi S, Morikawa S, Saijo M. Characterization of Glycoprotein-Mediated Entry of Severe Fever with Thrombocytopenia Syndrome Virus. *J Virol.* 2016, 12;90(11):5292-301.**

**Hotta A, Fujita O, Uda A, Yamamoto Y, Sharma N, Tanabayashi K, Yamada A, Morikawa S. Virulence of Representative Japanese *Francisella tularensis* and Immunologic Consequence of Infection in Mice. *Microbiol Immunol.* 2016, 60(3):168-76.**



Okutani A, Osaki M, Takamatsu D, Kaku Y, Inoue S, Morikawa S. Draft genome sequences of *Bacillus anthracis* strains stored for several decades in Japan. *Genome Announc.* 2015, 3(3). pii: e00633-15.

Hamamoto N, Uda A, Tobiume M, Park CH, Noguchi A, Kaku Y, Okutani A, Morikawa S, Inoue S. Association between RABV G Proteins Transported from the Perinuclear Space to Cell Surface Membrane and N-glycosylation of the Sequon at Asn204. *Jpn J Infect Dis.* 2015, 68(5):387-93.

Yoshikawa T, Shimojima M, Fukushi S, Tani H, Fukuma A, Taniguchi S, Singh H, Suda Y, Shirabe K, Toda S, Shimazu Y, Nomachi T, Gokuden M, Morimitsu T, Ando K, Yoshikawa A, Kan M, Uramoto M, Osako H, Kida K, Takimoto H, Kitamoto H, Terasoma F, Honda A, Maeda K, Takahashi T, Yamagishi T, Oishi K, Morikawa S, Saijo M. Phylogenetic and Geographic Relationships of Severe Fever With Thrombocytopenia Syndrome Virus in China, South Korea, and Japan. *J Infect Dis.* 2015, 212(6):889-98.

Ching PK, de los Reyes VC, Sucaldito MN, Tayag E, Columna-Vingno AB, Malbas FF Jr, Bolo GC Jr, Sejvar JJ, Eagles D, Playford G, Dueger E, Kaku Y, Morikawa S, Kuroda M, Marsh GA, McCullough S, Foxwell AR. Outbreak of Henipavirus Infection, Philippines. *Emerg Infect Dis.* 2015, 21(2):328-31.

Taguchi Y, Imaoka K, Kataoka M, Uda A, Nakatsu D, Horii-Okazaki S, Kunishige R, Kano F, Murata M. Yip1A, a novel host factor for the activation of the IRE1 pathway of the unfolded protein response during *Brucella* infection. *PLoS Pathog.* 2015;11(3):e1004747.

Yoshikawa T, Fukushi S, Tani H, Fukuma A, Taniguchi S, Toda S, Shimazu Y, Yano K, Morimitsu T, Ando K, Yoshikawa A, Kan M, Kato N, Motoya T, Kuzuguchi T, Nishino Y, Osako H, Yumisashi T, Kida K, Suzuki F, Takimoto H, Kitamoto H, Maeda K, Takahashi T, Yamagishi T, Oishi K, Morikawa S, Saijo M, Shimojima M. Sensitive and specific PCR systems for the detection of both Chinese and Japanese severe fever with thrombocytopenia syndrome virus strains, and the prediction of the patient survival based on the viral load. *J. Clin. Microbiol.* 2014, 52(9):3325-33.

Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine. *J. Virol.* 2014, 88(15): 8597-8614.

Uda A, Sekizuka T, Tanabayashi K, Fujita O, Kuroda M, Hotta A, Sugiura N, Sharma N, Morikawa S, Yamada A. Role of Pathogenicity Determinant Protein C (PdpC) in Determining the Virulence of the *Francisella tularensis* Subspecies *tularensis* SCHU. *PLoS One.* 2014, 9(2):e89075.

Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T, Kamei T, Honda M, Ninomiya D, Sakai T, Senba T, Kaneyuki S, Sakaguchi S, Satoh A, Hosokawa T, Kawabe Y, Kurihara S, Izumikawa K, Kohno S, Azuma T, Suemori K, Yasukawa M, Mizutani T, Omatsu T, Katayama Y, Miyahara M, Ijuin M, Doi K, Okuda M, Umeki K, Saito T, Fukushima K, Nakajima K, Yoshikawa T, Tani H, Fukushi S, Fukuma A, Ogata M, Shimojima M, Nakajima N, Nagata N, Katano H, Fukumoto H, Sato Y, Hasegawa H, Yamagishi T, Oishi K, Kurane I, Morikawa S, Saijo M. The First Identification and Retrospective Study of Severe Fever with Thrombocytopenia Syndrome in Japan. *J Inf Dis.*, 2014, 209(6):816-27.

Arai S, Nguyen ST, Boldgiv B, Fukui D, Araki K, Dang CN, Ohdachi SD, Nguyen NX, Pham TD, Boldbaatar B, Satoh H, Yoshikawa Y, Morikawa S, Tanaka-Taya K, Yanagihara R, Oishi K. Novel Bat-borne Hantavirus, Vietnam. *Emerg Infect Dis.* 2013, 19(7):1159-61.

Sharma N, Hotta A, Yamamoto Y, Fujita O, Uda A, Morikawa S, Yamada A, Tanabayashi K. Detection of Francisella tularensis-specific antibodies in patients with tularemia using a novel competitive enzyme-linked immunosorbent assay. *Clin Vaccine Immunol.* 2013, 20(1): 9-16

Tsutsuki H, Yahiro K, Ogura K, Ichimura K, Iyoda S, Ohnishi M, Nagasawa S, Seto K, Moss J, Noda M. Subtilase cytotoxin produced by locus of enterocyte effacement-negative Shiga-toxigenic Escherichia coli induces stress granule formation. *Cell Microbiol.* 2016. 18(7):1024-40.

Iguchi A, Iyoda S, Seto K, Nishii H, Ohnishi M, Mekata H, Ogura Y, Hayashi T. Six Novel O Genotypes from Shiga Toxin-Producing Escherichia coli. *Front Microbiol.* 2016. 20(7): 765.

Morita-Ishihara T, Iyoda S, Iguchi A, Ohnishi M. Secondary Shiga Toxin–Producing Escherichia coli Infection, Japan, 2010–2012. *Emerg Infect Dis*, 2016, 22(12), in press.

Njamkepo E, Fawal N, Tran-Dien A, Hawkey J, Strockbine N, Jenkins C, Talukder KA, Bercion R, Kuleshov K, Kolínská R, Russell JE, Kaftyreva L, Accou-Demartin M, Karas A, Vandenberg O, Mather AE, Mason CJ, Page AJ, Ramamurthy T, Bizet C, Gamian A, Carle I, Sow AG, Bouchier C, Wester AL, Lejay-Collin M, Fonkoua MC, Hello SL, Blaser MJ, Jernberg C, Ruckly C, Mérens A, Page AL, Aslett M, Roggentin P, Fruth A, Denamur E, Venkatesan M, Bercovier H, Bodhidatta L, Chiou CS, Clermont D, Colonna B, Egorova S, Pazhani GP, Ezernitchi AV, Guigon G, Harris SR, Izumiya H, Korzeniowska-Kowal A, Lutyńska A, Gouali M, Grimont F, Langendorf C, Marejková M, Peterson LA, Perez-Perez G, Ngandjio A, Podkolzin A, Souche E, Makarova M, Shipulin GA, Ye C, Žemličková H, Herpay M, Grimont PA, Parkhill J, Sansonetti P, Holt KE, Brisse S, Thomson NR, Weill FX. Global phylogeography and evolutionary history of Shigella dysenteriae type 1. *Nat Microbiol.* 2016. 1:16027.

Katanami Y, Kutsuna S, Morita M, Izumiya H, Ohnishi M, Yamamoto K, Takeshita N, Hayakawa K, Kanagawa S, Kato Y, Ohmagari N. Six Cases of Paratyphoid Fever Due to Salmonella Paratyphi A in Travelers Returning from Myanmar Between July 2014 and August 2015. *Am J Trop Med Hyg.* 2016. 95(3):571-3.

Kobayashi T, Kutsuna S, Hayakawa K, Kato Y, Ohmagari N, Uryu H, Yamada R, Kashiwa N, Nei T, Ehara A, Takei R, Mori N, Yamada Y, Hayasaka T, Kagawa N, Sugawara M, Suzaki A, Takahashi Y, Nishiyama H, Morita M, Izumiya H, Ohnishi M. Case Report: An Outbreak of Food-Borne Typhoid Fever Due to Salmonella enterica Serotype Typhi in Japan Reported for the First Time in 16 Years. *Am J Trop Med Hyg.* 2016. 94(2):289-91.

Johura FT, Parveen R, Islam A, Sadique A, Rahim MN, Monira S, Khan AR, Ahsan S, Ohnishi M, Watanabe H, Chakraborty S, George CM, Cravioto A, Navarro A, Hasan B, Alam M. Occurrence of Hybrid Escherichia coli Strains Carrying Shiga Toxin and Heat-Stable Toxin in Livestock of Bangladesh. *Front Public Health.* 2017 Jan 9;4:287.

Ishijima N, Lee KI, Kuwahara T, Nakayama-Imaohji H, Yoneda S, Iguchi A, Ogura Y, Hayashi T, Ohnishi M, Iyoda S. Identification of a New Virulent Clade in Enterohemorrhagic Escherichia coli O26:H11/H- Sequence Type 29. *Sci Rep.* 2017 Feb 23;7:43136.

Maeda E, Murakami K, Etoh Y, Onozuka D, Sera N, Asoshima N, Honda M, Narimatsu H, Iyoda S, Watahiki M, Fujimoto S. Does sequence type 33 of Shiga toxin-producing Escherichia coli O91 cause only mild symptoms? *J Clin Microbiol.* 2015. 53, 362-364.

Yahata Y, Misaki T, Ishida Y, Nagira M, Watahiki M, Isobe J, Terajima J, Iyoda S, Mitobe J, Ohnishi M, Sata T, Taniguchi K, Tada Y, Okabe N. Epidemiological analysis of a large enterohaemorrhagic Escherichia coli O111 outbreak in Japan associated with haemolytic uraemic syndrome and acute encephalopathy. *Epidemiol Infect.* 2015. 143, 2721-2732.

Harada T, Iguchi A, Iyoda S, Seto K, Taguchi M, Kumeda Y. Multiplex Real-Time PCR Assays for Screening of Shiga Toxin 1 and 2 Genes, Including All Known Subtypes, and Escherichia coli O26-, O111-, and O157-Specific Genes in Beef and Sprout Enrichment Cultures. *J Food Prot.* 2015. 78, 1800-1811.

Sakai T, Sawai T, Shimizu Y, Morimune T, Okuda Y, Maruo Y, Iyoda S, Takeuchi Y. Escherichia coli O121:H19 infection identified on microagglutination assay and PCR. *Pediatr Int.* 2015. 57, 1001-1003.

Saitoh T, Morita M, Shimada T, Izumiya H, Kanayama A, Oishi K, Ohnishi M, Sunagawa T. Increase in paratyphoid fever cases in Japanese travellers returning from Cambodia in 2013. *Epidemiol Infect.* 2015 14:1-5

Ogura Y, Mondal SI, Islam MR, Mako T, Arisawa K, Katsura K, Ooka T, Gotoh Y, Murase K, Ohnishi M, Hayashi T. The Shiga toxin 2 production level in enterohemorrhagic *Escherichia coli* O157:H7 is correlated with the subtypes of toxin-encoding phage. *Sci Rep.* 2015;5:16663.

Iyoda S, Manning SD, Seto K, Kimata K, Isobe J, Etoh Y, Ichihara S, Migita Y, Ogata K, Honda M, Kubota T, Kawano K, Matsumoto K, Kudaka J, Asai N, Yabata J, Tominaga K, Terajima J, Morita-Ishihara T, Izumiya H, Ogura Y, Saitoh T, Iguchi A, Kobayashi H, Hara-Kudo Y, and Ohnishi M, EHEC Working Group in Japan. Phylogenetic Clades 6 and 8 of enterohemorrhagic *Escherichia coli* O157:H7 with particular stx subtypes are more frequently found in isolates from hemolytic uremic syndrome patients than from asymptomatic carriers. *Open Forum Infect Dis.* 2014. 1, ofu061.

Sudo N, Soma A, Muto A, Iyoda S, Suh M, Kurihara N, Abe H, Tobe T, Ogura Y, Hayashi T, Kurokawa K, Ohnishi M, Sekine Y. A novel small regulatory RNA accelerates cell motility in enterohemorrhagic *Escherichia coli*. *J. Gen. Appl. Microbiol.* 2014. 60, 44-50.

Watahiki M, Isobe J, Kimata K, Shima T, Kanatani J, Shimizu M, Nagata A, Kawakami K, Yamada M, Izumiya H, Iyoda S, Morita-Ishihara T, Mitobe J, Terajima J, Ohnishi M, Sata T. Characterization of enterohemorrhagic *Escherichia coli* O111 and O157 strains isolated from outbreak patients in Japan. *J Clin Microbiol* 2014, 52, 2757-2763.

Igarashi T, Ito S, Sako M, Saitoh A, Hataya H, Mizuguchi M, Morishima T, Ohnishi K, Kawamura N, Kitayama H, Ashida A, Kaname S, Taneichi H, Tang J, Ohnishi M; Study group for establishing guidelines for the diagnosis and therapy of hemolytic uremic syndrome. Guidelines for the management and investigation of hemolytic uremic syndrome. *Clin Exp Nephrol.* 2014, 18, 525-557.

Fukushi S, Tani H, Yoshikawa T, Saijo M, Morikawa S. Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers. *Viruses.* 2012, 4(10):2097-114. (special issue: Arenaviruses).

Sayama Y, Demetria C, Saito M, Azul RR, Taniguchi S, Fukushi S, Yoshikawa T, Iizuka I, Mizutani T, Kurane I, Malbas FF Jr, Lupisan S, Catbagan DP, Animas SB, Morales RG, Lopez EL, Dazo KR, Cruz MS, Olveda R, Saijo M, Oshitani H, Morikawa S. A seroepidemiologic study of Reston ebolavirus in swine in the Philippines. *BMC Vet Res.* 2012, 8:82.

Lihoradova O, Kalveram B, Indran SV, Lokugamage N, Juelich TL, Hill TE, Tseng CT, Gong B, Fukushi S, Morikawa S, Freiberg AN, Ikegami T. The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. *J Virol.* 2012, 86(14):7650-61.

**Fukushi S, Nakauchi M, Mizutani T, Saijo M, Kurane I, Morikawa S. Antigen-capture ELISA for the detection of Rift Valley fever virus nucleoprotein using new monoclonal antibodies. J Virol Methods. 2012, 180(1-2):68-74.**

**Arai S, Gu SH, Baek LJ, Tabara K, Bennett SN, Oh HS, Takada N, Kang HJ, Tanaka-Taya K, Morikawa S, Okabe N, Yanagihara R, Song JW. Divergent ancestral lineages of newfound hantaviruses harbored by phylogenetically related crocidurine shrew species in Korea. Virology. 2012, 424(2):99-105.**

**Tatsuya Nishi, Hiroyuki Onozato, Seiichi Ohashi, Katsuhiko Fukai, Manabu Yamada, Kazuki Morioka, Toru Kanno, Construction and characterization of a full-length infectious cDNA clone of foot-and-mouth disease virus strain O/JPN/2010 isolated in Japan in 2010. Research in Veterinary Science 2016 Jun;106:165-9. doi: 10.1016/j.rvsc.2016.03.017. Epub 2016 Apr 9.**

## Confidence-Building Measure "E"

### Declaration of legislation, regulations and other measures

#### Form E

### Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures <sup>3</sup>	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(b) Exports of micro-organisms <sup>4</sup> and toxins	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No
(c) Imports of micro-organisms <sup>11</sup> and toxins	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(d) Biosafety <sup>5</sup> and biosecurity <sup>6</sup>	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No

---

<sup>3</sup> Including guidelines.

<sup>4</sup> Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

<sup>5</sup> In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

<sup>6</sup> In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

**Name of legislation, regulations, and other measures:**

**Foreign exchange and Foreign Trade Law (1948)**

**Law on Implementing the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction and the Other Conventions (1982)**

**Cabinet Order for the Enforcement of the Law on Implementing the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction (1995)**

**The Law Concerning the Prevention of Infections and Medical Care for Patients of Infections (1998)**

## **Confidence-Building Measure "F"**

### **Declaration of past activities in offensive and/or defensive biological research and development programmes**

#### **Form F**

1. Date of entry into force of the Convention for the State Party

**June 8, 1982**

2. Past offensive biological research and development programmes:

**None**

3. Past defensive biological research and development programmes:

**None**



## Confidence-Building Measure "G"

### Declaration of vaccine production facilities

#### Form G

### Declaration of vaccine production facilities

No.	Name of Facility	Location (postal address)	General Description of the Types of Diseases Covered
1	Denka Seiken Co., Ltd	2-1-1 Nihonbashi Muromachi, Chuo-ku, Tokyo, Japan	Influenza, Tetanus
2	Kitasato Daiichi Sankyo Vaccine Co.,Ltd	6-111 Arai, Kitamoto-shi, Saitama, Japan	Influenza, Rubella, Diphtheria, Tetanus, Pertussis, Measles, Mumps, Poliomyelitis
3	Takeda Pharmaceutical Co.,Ltd	4-1-1 Doshomachi, Chuo-ku, Osaka, Japan	Influenza, Diphtheria, Tetanus, Pertussis, Measles, Mumps, Rubella
4	The Research Foundation for Microbial Diseases of Osaka University (BIKEN)	3-1 Yamadaoka, Suita-shi, Osaka, Japan	Influenza, Diphtheria, Tetanus, Varicella, Japanese Encephalitis, Pertussis, Measles, Rubella, Poliomyelitis
5	The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)	1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto, Japan	Influenza, Rabies, Diphtheria, Tetanus, Japanese Encephalitis, Pertussis, Mumps, Hepatitis A, Hepatitis B, Poliomyelitis
6	Japan BCG Laboratory	4-2-6 Kohinata, Bunkyo-ku, Tokyo, Japan	Tuberculosis